Welcome to our dedicated page for eXoZymes news (Ticker: EXOZ), a resource for investors and traders seeking the latest updates and insights on eXoZymes stock.
eXoZymes Inc. develops AI-enhanced enzymes and a cell-free biomanufacturing platform for producing high-value natural products from abundant feedstock. Company news centers on exozymes, enzyme cascades operating outside living cells, and the use of the platform in nutraceuticals, novel medicines, active pharmaceutical ingredients, biofuels, food flavors, cosmetics, and valuable chemicals.
Recurring updates cover N-trans-caffeoyltyramine, or NCT, NCTx commercialization activity, pilot-scale production and technology-transfer work, partner validation, strategic focus on pharmaceutical and nutraceutical markets, accelerator participation, investor presentations, and periodic operating results communications.
eXoZymes (NASDAQ:EXOZ) priced a public offering of units at $18.00 per unit, each containing two common shares and one warrant. The company sold 592,270 shares and 296,135 warrants, for expected gross proceeds of about $5.33 million before expenses.
The underwriter has a 45-day option for up to 44,420 additional units. Warrants have a $11.24 exercise price, a five-year term, reset and redemption features, and will not be listed. Proceeds will support NCT-related development, R&D, and general corporate purposes.
eXoZymes (NASDAQ:EXOZ) announced graduation from the Shell GameChanger Accelerator powered by NLR on May 7, 2026. From 2023–2026 the partnership supported advancement of eXoZymes' cell-free biomanufacturing platform toward commercial viability through technical guidance, separations evaluation, and technoeconomic and lifecycle analysis.
eXoZymes (NASDAQ:EXOZ) CCO Damien Perriman detailed the commercial path for cell-free biomanufacturing and the company’s first spinout, NCTx, on the Grow Everything podcast on April 10, 2026. Perriman said NCTx targets a supplement pathway for NCT while evaluating pharmaceutical options.
The episode highlighted third-party validation: a 100-fold tech transfer with ~99% conversion and 99.6% purity of NCT, which Perriman described as proof of the cell-free platform’s scale-up and tech-transfer capability.
eXoZymes (NASDAQ:EXOZ) provided a fiscal 2025 update on March 31, 2026, reporting increased operating investment, platform validation, and financing preparations.
Key figures: Operating expenses $9.72M, Net loss $9.16M, and Cash $3.04M as of December 31, 2025. The company advanced pilot-scale cell-free biomanufacturing and filed an S-3 in January 2026 ahead of an imminent financing round.
eXoZymes (NASDAQ:EXOZ) will host a webinar on Tuesday, March 31, 2026 at 5:30 PM ET to review fourth quarter and full year 2025 results. CEO Michael Heltzen and select management will discuss recent developments, ongoing initiatives, anticipated milestones, and hold a Q&A.
A press release with results will be issued prior to the call. Investors can pre-register and access the live webinar via the company’s investor relations site at https://exozymes.com/investor.
eXoZymes (NASDAQ:EXOZ) reported a successful pilot-scale validation with Cayman Chemical, advancing its cell-free biomanufacturing from 1L to a 100-liter run in under one year. The partner produced over 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) at 99.6% purity with ~99% conversion.
This external, independent run demonstrated scalability, robustness under real-world conditions (pH variation, precipitation), and material available for formulation, validation, and commercialization discussions.
eXoZymes (NASDAQ:EXOZ) announced that CCO Damien Perriman will present a solution for scaling production of NCT at the MISTA Symposium Healthspan on March 18, 2026 in San Francisco. The talk will cover NCT's role in metabolic health and cell-free enzyme production using the company's AI-designed exozyme platform.
The company says its cell-free enzyme cascades aim to enable scalable supply of a rare plant-derived molecule for nutraceutical and pharmaceutical applications.
eXoZymes (NASDAQ:EXOZ) unveiled a refreshed brand identity and redesigned website on February 10, 2026, aligning external presentation with a refined strategic focus on pharmaceutical and high-value nutraceutical markets.
The company said it will prioritize its AI-designed, cell-free enzyme cascade platform to target regulated, high-margin applications and pursue platform leverage, partnerships, and IP development.
eXoZymes (NASDAQ:EXOZ) reported results from a 100-liter pilot run producing N-trans-caffeoyltyramine (NCT): ~99% reaction conversion, 91% process recovery, 90% isolated yield, 535 grams isolated, and 99.6% pharma-grade purity. The run was executed by Cayman Chemical, demonstrating protocol transferability and improved reaction performance at larger scale. eXoZymes plans 2026 work to establish commercial supply chains, expand volumes, form strategic partnerships, and finalize technology-transfer packages for commercial manufacturing and formulation development.
eXoZymes (NASDAQ:EXOZ) reported a successful 100× scale-up of its N-trans-caffeoyltyramine (NCT) production using its cell-free, exozyme-based biomanufacturing platform on December 11, 2025. The scaled run delivered >99% conversion from feedstock to product and was executed under partner-operated conditions by Cayman Chemical, demonstrating process transferability and robustness. eXoZymes said downstream isolation and full data analysis are ongoing, with additional technical details expected in early 2026.